US clinical-stage biotech Vigil Neuroscience (Nasdaq: VIGL) today announced a disappointing update on the Phase II IGNITE ...

Vigil on Wednesday said it is ending a Phase 2 study of iluzanebart in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, or ALSP, after the drug showed no ...

Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of ...